Seattle's hometown billionaire and biotech entrepreneur Paul Allen is chipping $20 million into a new infusion of cash for Omeros, which also hauled in $5 million from the state's life sciences fund. The money will be used to finance Omeros' quest for new drugs that can hit some 100 potential GPCR targets--a field that backers expect will deliver new therapies for currently "undruggable" targets.
Read more: Billionaire Allen helps inject $25M into Seattle's Omeros - FierceBiotech
